Subir material

Suba sus trabajos a SEDICI, para mejorar notoriamente su visibilidad e impacto

 

Mostrar el registro sencillo del ítem

dc.date.accessioned 2020-05-22T13:22:11Z
dc.date.available 2020-05-22T13:22:11Z
dc.date.issued 2015
dc.identifier.uri http://sedici.unlp.edu.ar/handle/10915/96533
dc.description.abstract Telomeres are specialized nucleoproteic complexes localized at the ends of eukaryotic chromosomes, that maintain their stability and integrity. They protect chromosome ends from fusion and from being recognized as sites of DNA damage, i.e., they distinguish natural DNA ends from DNA ends resulting from breakage events. In mammalian cells, telomeres consist of tandem arrays of the hexanucleotide TTAGGG, oriented 5′ to 3′ towards the end of the chromosomes and associated proteins (the so-called “shelterin” complex), and a large non-coding RNA (named TERRA) which forms an integral component of telomeric heterochromatin. Telomere length is maintained by a dynamic process of telomere shortening and lengthening. Shortening can occur due to nucleolytic degradation and incomplete DNA replication due to the inability of lagging strand synthesis to completely replicate chromosomal ends (i.e., the “end replication problem”), whereas lengthening is primarily accomplished by the action of the enzyme telomerase and occasionally by the so-called Alternative Lengthening of Telomeres (“ALT”) mechanism, which involves homologous recombination. The maintenance of telomere function is crucial for genomic stability and cell viability. Cells respond to dysfunctional telomeres by undergoing senescence, cell death, or genomic instability. Since telomeres play a fundamental role in maintaining chromosomal/genomic stability and telomerase activity and telomere lengthening play a key role in cancer development and progression, a proper knowledge of the effects of chemotherapeutic drugs on telomere length and telomerase activity in normal as well as tumor cells is of great importance to understand the genomic instability associated with chemotherapy regimens. Therefore, in this review we will summarize our current knowledge concerning the main data available about the effects of chemotherapeutic drugs on telomere length and telomerase activity in mammalian cells. en
dc.language en es
dc.subject Telomere es
dc.subject Telomere length es
dc.subject Telomerase es
dc.subject Anticancer drugs es
dc.subject Chemotherapeutic drugs es
dc.title Effect of chemotherapeutic drugs on telomere length and telomerase activity en
dc.type Articulo es
sedici.identifier.uri https://ri.conicet.gov.ar/11336/66877 es
sedici.identifier.uri https://www.smartscitech.com/index.php/TT/article/view/751 es
sedici.identifier.other http://dx.doi.org/10.14800/tt.1488 es
sedici.identifier.other hdl:11336/66877 es
sedici.identifier.issn 2378-1378 es
sedici.creator.person Bolzán, Alejandro Daniel es
sedici.subject.materias Farmacia es
sedici.subject.materias Ciencias Exactas es
sedici.description.fulltext true es
mods.originInfo.place Instituto Multidisciplinario de Biología Celular es
sedici.subtype Articulo es
sedici.rights.license Creative Commons Attribution 4.0 International (CC BY 4.0)
sedici.rights.uri http://creativecommons.org/licenses/by/4.0/
sedici.description.peerReview peer-review es
sedici.relation.journalTitle Telomere and Telomerase es
sedici.relation.journalVolumeAndIssue vol. 3 es


Descargar archivos

Este ítem aparece en la(s) siguiente(s) colección(ones)

Creative Commons Attribution 4.0 International (CC BY 4.0) Excepto donde se diga explícitamente, este item se publica bajo la siguiente licencia Creative Commons Attribution 4.0 International (CC BY 4.0)